Cargando…

Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies

Breast cancer accounts for approximately 25% of cancer cases and 16.5% of cancer deaths in women, and the World Health Organization predicts that the number of new cases will increase by almost 70% over the next two decades, mainly due to an ageing population. Effective diagnostic and treatment stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafik, Salma T., Vaidya, Jayant S., MacRobert, Alexander J., Yaghini, Elnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095028/
https://www.ncbi.nlm.nih.gov/pubmed/37048731
http://dx.doi.org/10.3390/jcm12072648
_version_ 1785023982851850240
author Rafik, Salma T.
Vaidya, Jayant S.
MacRobert, Alexander J.
Yaghini, Elnaz
author_facet Rafik, Salma T.
Vaidya, Jayant S.
MacRobert, Alexander J.
Yaghini, Elnaz
author_sort Rafik, Salma T.
collection PubMed
description Breast cancer accounts for approximately 25% of cancer cases and 16.5% of cancer deaths in women, and the World Health Organization predicts that the number of new cases will increase by almost 70% over the next two decades, mainly due to an ageing population. Effective diagnostic and treatment strategies are, therefore, urgently required for improving cure rates among patients since current therapeutic modalities have many limitations and side effects. Nanomedicine is evolving as a promising approach for cancer management, including breast cancer, and various types of organic and inorganic nanomaterials have been investigated for their role in breast cancer diagnosis and treatment. Following an overview on breast cancer characteristics and pathogenesis and challenges of the current treatment strategies, the therapeutic potential of biocompatible organic-based nanoparticles such as liposomes and polymeric micelles that have been tested in breast cancer models are reviewed. The efficacies of different drug delivery and targeting strategies are documented, ranging from synthetic to cell-derived nanoformulations together with a summary of the interaction of nanoparticles with externally applied energy such as radiotherapy. The clinical translation of nanoformulations for breast cancer treatment is summarized including those undergoing clinical trials.
format Online
Article
Text
id pubmed-10095028
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100950282023-04-13 Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies Rafik, Salma T. Vaidya, Jayant S. MacRobert, Alexander J. Yaghini, Elnaz J Clin Med Review Breast cancer accounts for approximately 25% of cancer cases and 16.5% of cancer deaths in women, and the World Health Organization predicts that the number of new cases will increase by almost 70% over the next two decades, mainly due to an ageing population. Effective diagnostic and treatment strategies are, therefore, urgently required for improving cure rates among patients since current therapeutic modalities have many limitations and side effects. Nanomedicine is evolving as a promising approach for cancer management, including breast cancer, and various types of organic and inorganic nanomaterials have been investigated for their role in breast cancer diagnosis and treatment. Following an overview on breast cancer characteristics and pathogenesis and challenges of the current treatment strategies, the therapeutic potential of biocompatible organic-based nanoparticles such as liposomes and polymeric micelles that have been tested in breast cancer models are reviewed. The efficacies of different drug delivery and targeting strategies are documented, ranging from synthetic to cell-derived nanoformulations together with a summary of the interaction of nanoparticles with externally applied energy such as radiotherapy. The clinical translation of nanoformulations for breast cancer treatment is summarized including those undergoing clinical trials. MDPI 2023-04-02 /pmc/articles/PMC10095028/ /pubmed/37048731 http://dx.doi.org/10.3390/jcm12072648 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rafik, Salma T.
Vaidya, Jayant S.
MacRobert, Alexander J.
Yaghini, Elnaz
Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies
title Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies
title_full Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies
title_fullStr Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies
title_full_unstemmed Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies
title_short Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies
title_sort organic nanodelivery systems as a new platform in the management of breast cancer: a comprehensive review from preclinical to clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095028/
https://www.ncbi.nlm.nih.gov/pubmed/37048731
http://dx.doi.org/10.3390/jcm12072648
work_keys_str_mv AT rafiksalmat organicnanodeliverysystemsasanewplatforminthemanagementofbreastcanceracomprehensivereviewfrompreclinicaltoclinicalstudies
AT vaidyajayants organicnanodeliverysystemsasanewplatforminthemanagementofbreastcanceracomprehensivereviewfrompreclinicaltoclinicalstudies
AT macrobertalexanderj organicnanodeliverysystemsasanewplatforminthemanagementofbreastcanceracomprehensivereviewfrompreclinicaltoclinicalstudies
AT yaghinielnaz organicnanodeliverysystemsasanewplatforminthemanagementofbreastcanceracomprehensivereviewfrompreclinicaltoclinicalstudies